Brief: Dermapharm H1 Adjusted EBITDA EUR 168 Million
Aug 16 (Reuters) - Dermapharm H1 EBITDA EUR 137 million. * H1 EBITDA margin 23.5% * H1 adjusted EBITDA margin 28.9% * H1 revenue EUR 582 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit